MedTrace Logo

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season

NCT01633749 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2012-08-06

No results posted yet for this study

Summary

Annual study to investigate influenza vaccine (flu vaccine) developed for the 2012/2013 season for the prevention of influenza infection. The immunizing effect is being investigated, as well as its tolerability and safety.

Conditions

  • Prophylaxis of Influenza

Interventions

BIOLOGICAL

Trivalent influenza subunit vaccine Influvac

3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1

Sponsors & Collaborators

  • Abbott Biologicals

    lead INDUSTRY

Principal Investigators

  • Serge van de Witte, PhD · Abbott Healthcare Products BV

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01633749 on ClinicalTrials.gov